Estimated return — disclosed long book
What Patient Capital Management LLC’s US-listed long positions did, derived from the share counts and market values in consecutive 13F filings, shown against SPY over exactly the same quarters. This is not the fund’s return. A 13F excludes shorts, bonds, cash, non-US listings and derivatives, says nothing about fees or leverage, and only sees positions held at both quarter ends. The fund figure is a price return while SPY is a total return, so the comparison is tilted against the manager by roughly a dividend yield.
Q2 2026
+12.8%
SPY +15.1%▼ -2.4%
2026 YTD(2Q so far)
+7.1%
SPY +10.1%▼ -3.0%
By calendar year
| Year | Estimated | SPY | Difference |
|---|---|---|---|
| 2025 | +19.8% | +17.7% | +2.1% |
| 2024 | +17.9% | +24.9% | -7.0% |
| 2023 | +36.4% | +26.2% | +10.2% |
| 2022 | -31.0% | -18.2% | -12.8% |